United Therapeutics Corporation is a biopharmaceutical company that develops and markets therapies for serious diseases with unmet medical needs, primarily pulmonary arterial hypertension (PAH) and high-risk neuroblastoma. The company's commercial portfolio includes Tyvaso DPI and Nebulized Tyvaso for PAH and pulmonary hypertension associated with interstitial lung disease, Remodulin and Remunity pumps for continuous subcutaneous or intravenous administration, Orenitram oral tablets, and Adcirca tablets. It also sells Unituxin for the treatment of high-risk neuroblastoma in the United States, Canada, and Japan. United Therapeutics serves markets in the United States, Europe, Japan, Asia, the Middle East, and Latin America. The company was founded by Martine Rothblatt to address rare diseases and focuses on expanding the availability of transplantable organs through organ manufacturing technologies.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage unither.com
Sector Healthcare IR page unither.com
Tags
pulmonary arterial hypertension, neuroblastoma, rare diseases, prostacyclin analogues, pde-5 inhibitors, organ manufacturing, specialty pharmaceuticals, Tyvaso DPI, Nebulized Tyvaso, Remodulin, Remunity, RemunityPRO, Orenitram, Adcirca, Unituxin, MannKind
Press page —

Metrics

Valuation  
Market cap $ 24.634B
Market cap (USD) $ 24.634B
P/E 21.97
PEG 0.98
P/BV 3.93
P/S 7.73
P/OCF 17.23
P/FCF 28.41
Dividend yield —
Turnover / mcap —
Returns  
ROE 19.7%
ROI 18.8%
ROIC 16.4%
Profit margin 41.9%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 22.4%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 55
Quality score 44.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999 FY 1998
Revenue 3.183B 2.877B 2.328B 1.936B 1.686B 1.483B 1.449B 1.628B 1.725B 1.599B 1.466B 1.289B 1.117B 916.076M 743.183M 603.831M 369.848M 281.497M 210.943M 159.632M 115.915M 73.59M 53.341M 30.12M 5.732M — — —
Net profit 1.335B 1.195B 984.8M 727.3M 475.8M 514.8M -104.5M 589.2M 417.9M 713.7M 651.639M 340.074M 174.56M 304.442M 217.868M 105.916M 19.462M -42.789M 19.859M 73.965M 65.016M 15.449M -9.969M -23.651M -37.288M -75.608M -33.507M -12.835M
Free cash flow 1.041B 1.081B 747.6M 663.7M 477.4M 696.4M -290.3M 594M 387.9M 605.6M 332.969M 307.82M 393.357M 211.723M 214.218M 192.892M 2.224M -173.587M 10.425M 36.15M 37.583M 15.561M -15.566M -25.839M -39.586M -31.755M -25.688M -10.63M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999 FY 1998
Share price 487.25 352.84 219.89 278.09 216.08 151.79 88.08 108.9 147.95 143.43 156.61 129.49 113.08 53.43 47.26 63.25 52.59 54.36 99.3 52.8 68.9 — — — — — — —
Price performance 12m 0.38 0.6 -0.21 0.29 0.42 0.72 -0.19 -0.26 0.03 -0.08 0.21 0.15 1.12 0.13 -0.25 0.2 -0.03 -0.45 0.88 -0.23 — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 215M 297M 176M 151M 157M 199M 220M 279M 279M 350M
↳ YoY growth +11.2% +38.5% -40.9% -13.8% +4.0% +26.2% +10.9% +26.5% +0.1% +25.4%
↳ 5y CAGR +19.3% +20.6% +6.8% -1.4% -4.0% -1.5% -5.8% +9.7% +13.0% +17.3%
Lease liabilities (USD) — — 8.2M 4.8M — — — — — —
Cash and deposits (USD) 1.02B 705M 669M 738M 739M 895M 961M 1.21B 1.7B 1.56B
Right-of-use assets (USD) — — 8.2M 4.8M — — — — — —
Cash flow detail
Operating cash flow (USD) 644M 474M 778M -207M 756M 598M 803M 978M 1.33B 1.56B
Purchases of property, plant and equipment (USD) -38M -86.3M -184M -83.7M -59.3M -121M -139M -230M -247M -521M
Purchases of intangible assets (USD) -5.2M — — — — — — 0.00 0.00 -5.5M
Change in receivables (cash effect) (USD) -21.7M -82.7M 121M 24.4M -6M -41.3M -21.7M -58.5M -400,000 -70.9M
Change in inventories (cash effect) (USD) -24.5M -500,000 9.3M 12.9M 10.3M -7.5M -13.4M -13.6M -46.9M -52.6M
Change in payables (cash effect) (USD) 600,000 66.2M -11M -16.3M 38.6M -12.5M 44.5M 57.1M 42.7M 97.9M
Share buybacks (cash effect) (USD) -500M -250M — — — — 0.00 0.00 -1B -1B
Interest paid (cash effect) (USD) -1.5M -7.5M -9.4M -41M -20.7M -16.2M -29.1M -56M -40.2M -13.5M
Income taxes paid (cash effect) (USD) -362M -347M -103M -120M -92.8M -153M -276M -333M -401M -313M
Share-based compensation (USD) 12.1M 73.5M -26.4M 45.4M 164M 139M 107M 39.1M 144M 148M
Operating cash flow before change in receivables (USD) 665M 557M 657M -231M 762M 640M 824M 1.04B 1.33B 1.63B
Free cash flow (OCF - PPE - intangibles) (USD) 600M 388M 594M -290M 696M 477M 664M 748M 1.08B 1.04B
Income detail
Research and development expense (USD) 148M 265M 358M 1.18B 358M 540M 323M 408M 481M 550M
↳ 5y CAGR -3.9% +8.8% +3.6% +37.3% +7.9% +29.6% +4.1% +2.7% -16.5% +9.0%
Total comprehensive income (USD) 717M 415M 601M -111M 515M 467M 695M 1.03B 1.2B 1.34B
Comprehensive income to owners (USD) 717M 415M 601M -111M 515M 467M 695M 1.03B 1.2B 1.34B
Provision for credit losses (USD) 0.00 0.00 — — — — — — — —
Credit cost ratio (credit losses / average receivables) (%) 0.0% 0.0% — — — — — — — —
Reported Feb 21, 2018 Feb 21, 2018 May 1, 2019 Feb 26, 2020 Feb 24, 2021 Feb 24, 2022 Feb 26, 2025 Feb 25, 2026 Feb 25, 2026 Feb 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Download PDF Version

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2026. Total revenues in the third quarter of 2026 increased by four percent year-over-year to $832.5 million, compared to $799.5 million in the third quarter of 2025.

“United Therapeutics is entering a period of extraordinary growth. We are advancing a portfolio of new therapies designed to exponentially increase the number of patients we can serve,” said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics.

“Our record third quarter revenue performance reflects a business operating at a very high level, driven by strong commercial momentum and focused execution across our organization,” said Michael Benkowitz, President and Chief Operating Officer of United Therapeutics. “Our strategies are delivering, securing an increasingly strong position to leverage our commercial operations. With a durable and robust foundation combined with significant new opportunities across cardiopulmonary and respiratory medicine rapidly approaching, we believe we have the strongest growth outlook in our history.”

Third Quarter 2026 Financial Results

Key financial highlights include (dollars in millions, except per share data):

**Three Months Ended **September 30, Dollar Change Percentage Change
2026 2025
Total revenues $ 832.5 $ 799.5 $ 33.0 4 %
Net income $ 258.6 $ 338.7 $ (80.1 ) (24 )%
Net income, per basic share $ 6.06 $ 7.73 $ (1.67 ) (22 )%
Net income, per diluted share $ 5.71 $ 7.16 $ (1.45 ) (20 )%

Revenues

The table below presents the components of total revenues (dollars in millions):

**Three Months Ended **September 30, Dollar Change PercentageChange
2026 2025
Net product sales:
Tyvaso DPI® $ 378.5 $ 336.2 $ 42.3 13 %
Nebulized Tyvaso® 125.3 141.8 (16.5 ) (12 )%
Total Tyvaso 503.8 478.0 25.8 5 %
Remodulin®(1) 122.0 125.9 (3.9 ) (3 )%
Orenitram® 145.0 131.1 13.9 11 %
Unituxin® 52.3 47.9 4.4 9 %
Adcirca® 4.5 9.7 (5.2 ) (54 )%
Other 4.9 6.9 (2.0 ) (29 )%
Total revenues $ 832.5 $ 799.5 $ 33.0 4 %
(1) Net product sales include sales of infusion devices, including the Remunity® and RemunityPRO® Pumps.

Total Tyvaso revenues increased by five percent to $503.8 million in the third quarter of 2026, as compared to $478.0 million in the third quarter of 2025, driven by growth in Tyvaso DPI revenues, partially offset by a decrease in Nebulized Tyvaso revenues. The growth in Tyvaso DPI revenues resulted primarily from an increase in quantities sold of $43.9 million and a price increase, partially offset by higher gross-to-net deductions. The decrease in Nebulized Tyvaso revenues resulted primarily from a decrease in U.S. quantities sold of $20.0 million, partially offset by a price increase. We believe the availability of competitive therapies negatively impacted sales of Nebulized Tyvaso, Tyvaso DPI, and Remodulin for the three months ended September 30, 2026. The growth in Orenitram revenues resulted primarily from an increase in quantities sold of $14.9 million and a price increase, partially offset by an increase in gross-to-net deductions.

The table below presents the breakdown of total revenues between the United States and rest-of-world (ROW) (in millions):

Three Months Ended September 30,
2026 2025
U.S. ROW Total U.S. ROW Total
Net product sales:
Tyvaso DPI $ 378.2 $ 0.3 $ 378.5 $ 336.2 $ — $ 336.2
Nebulized Tyvaso 118.0 7.3 125.3 133.9 7.9 141.8
Total Tyvaso 496.2 7.6 503.8 470.1 7.9 478.0
Remodulin(1) 108.5 13.5 122.0 110.7 15.2 125.9
Orenitram 145.0 — 145.0 131.1 — 131.1
Unituxin 49.9 2.4 52.3 46.5 1.4 47.9
Adcirca 4.5 — 4.5 9.7 — 9.7
Other 4.4 0.5 4.9 6.7 0.2 6.9
Total revenues $ 808.5 $ 24.0 $ 832.5 $ 774.8 $ 24.7 $ 799.5
(1) Net product sales include sales of infusion devices, including the Remunity and RemunityPRO Pumps.

Expenses

Cost of sales. The table below summarizes cost of sales by major category (dollars in millions):

**Three Months Ended **September 30, Dollar Change Percentage Change
2026 2025
Category:
Cost of sales $ 98.0 $ 100.0 $ (2.0 ) (2 )%
Share-based compensation expense(1) 1.1 0.9 0.2 22 %
Total cost of sales $ 99.1 $ 100.9 $ (1.8 ) (2 )%
(1) See Share-based compensation expense below.

Research and development expense. The table below summarizes the nature of research and development expense by major expense category (dollars in millions):

**Three Months Ended **September 30, Dollar Change Percentage Change
2026 2025
Category:
External research and development(1) $ 77.1 $ 63.5 $ 13.6 21 %
Internal research and development(2) 61.0 50.8 10.2 20 %
Share-based compensation expense(3) 11.1 8.4 2.7 32 %
Other(4) 130.0 4.8 125.2 NM(5)
Total research and development expense $ 279.2 $ 127.5 $ 151.7 119 %
(1) External research and development primarily includes fees paid to third parties (such as clinical trial sites, contract research organizations, and contract laboratories) for preclinical and clinical studies and payments to third-party contract manufacturers before regulatory approval of the relevant product.
(2) Internal research and development primarily includes salary-related expenses for research and development functions, internal costs to manufacture product candidates before regulatory approval, and internal facilities-related expenses, including depreciation, related to research and development activities.
(3) See Share-based compensation expense below.
(4) Other primarily includes costs to acquire certain in-process research and development (IPR&D) assets, upfront fees and milestone payments to third parties under license agreements related to development-stage products, and adjustments to the fair value of our contingent consideration obligations.
(5) Calculation is not meaningful.

Research and development, excluding share-based compensation. The increase in research and development expense for the three months ended September 30, 2026, as compared to the same period in 2025, was primarily due to: (1) an increase in IPR&D expense in connection with the acquisition of Thymmune Therapeutics, Inc. (Thymmune), which we accounted for as an asset acquisition; (2) an increase in expenditures related to manufactured organ and organ alternative projects; and (3) an increase in expenditures related to cardiopulmonary treatment projects.

Selling, general, and administrative expense. The table below summarizes selling, general, and administrative expense by major category (dollars in millions):

**Three Months Ended **September 30, Dollar Change Percentage Change
2026 2025
Category:
General and administrative(1) $ 143.1 $ 123.7 $ 19.4 16 %
Litigation accrual (66.5 ) 0.8 (67.3 ) NM(3)
Sales and marketing 41.0 28.3 12.7 45 %
Share-based compensation expense(2) 28.8 29.8 (1.0 ) (3 )%
Total selling, general, and administrative expense $ 146.4 $ 182.6 $ (36.2 ) (20 )%
(1) Excluding litigation accrual. See Litigation accrual section below.
(2) See Share-based compensation expense below.
(3) Calculation is not meaningful.

General and administrative, excluding litigation accrual and share-based compensation. The increase in general and administrative expense for the three months ended September 30, 2026, as compared to the same period in 2025, was primarily due to: (1) an increase in personnel expense due to growth in headcount; (2) an increase in legal expenses related to litigation matters; and (3) an increase in consulting expenses.

Litigation accrual. The change in litigation accrual for the three months ended September 30, 2026, as compared to the same period in 2025, was primarily due to the reversal of a previously accrued liability related to the Sandoz litigation matter, which we agreed to settle in October 2026 in connection with our settlement with Liquidia Technologies, Inc. The Sandoz litigation matter was dismissed on October 28, 2026. See Note 12—Litigation to our consolidated financial statements included in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.

Sales and marketing, excluding share-based compensation. The increase in sales and marketing expense for the three months ended September 30, 2026, as compared to the same period in 2025, was primarily due to an increase in personnel expense due to growth in headcount.

Share-based compensation expense. The table below summarizes share-based compensation expense by major category (dollars in millions):

**Three Months Ended **September 30, Dollar Change Percentage Change
2026 2025
Category:
Stock options $ 11.0 $ 11.3 $ (0.3 ) (3 )%
Restricted stock units 29.1 27.1 2.0 7 %
Employee stock purchase plan 0.9 0.7 0.2 29 %
Total share-based compensation expense $ 41.0 $ 39.1 $ 1.9 5 %

Interest income. Interest income was $33.7 million and $46.4 million for the three months ended September 30, 2026 and 2025, respectively. The decrease in interest income was primarily due to a decrease in marketable investments due to the sale of securities to fund our three accelerated share repurchase agreements with Citibank, N.A. (Citi): two agreements executed in March 2026 to repurchase approximately $1.5 billion of our common stock (the March 2026 ASRs) and one agreement executed in September 2026 to repurchase approximately $477.6 million of our common stock (the September 2026 ASR).

Other income, net. Other income, net was $34.2 million and $6.1 million for the three months ended September 30, 2026 and 2025, respectively. The increase in other income was primarily due to net realized and unrealized gains on equity securities.

Income tax expense. Income tax expense for the three months ended September 30, 2026 and 2025 was $114.2 million and $99.3 million, respectively. Our effective income tax rate (ETR) for the three months ended September 30, 2026 and 2025 was 31 percent and 23 percent, respectively. Our ETR for the three months ended September 30, 2026 increased compared to our ETR for the three months ended September 30, 2025, primarily due to nondeductible IPR&D expense related to the acquisition of Thymmune, which was capitalized for tax purposes into the basis of the stock acquired.

Share repurchases. In March 2026, our Board of Directors approved a share repurchase program authorizing up to $2.0 billion in aggregate repurchases of our common stock. In connection with the repurchase program, we entered into three accelerated share repurchase agreements with Citi: the March 2026 ASRs and the September 2026 ASR. During the three months ended September 30, 2026, we received an additional 215,948 shares of our common stock upon final settlement of the second of the March 2026 ASRs and received an initial delivery of 719,376 shares of our common stock under the September 2026 ASR. The final settlement of the September 2026 ASR is expected to occur in the fourth quarter of 2026.

During the three months ended September 30, 2026, we adopted a Rule 10b5-1 trading plan and repurchased 45,070 shares of our common stock at an aggregate cost of $22.4 million under this share repurchase authorization. The September 2026 ASR utilized the remaining $477.6 million of the share repurchase program authorization, and no amount remained available under the share repurchase program authorized by our Board in March 2026.

During the three months ended September 30, 2026, we repurchased a total of 980,394 shares of our common stock that we currently hold as treasury stock in our consolidated balance sheets as of September 30, 2026.

In October 2026, our Board of Directors approved a share repurchase program authorizing up to $2.0 billion in aggregate repurchases of our common stock through October 21, 2027.

Webcast

We will host a webcast to discuss our third quarter 2026 financial results on Wednesday, November 4, 2026, at 9:00 a.m. Eastern Time. The webcast can be accessed live via our website at https://ir.unither.com/events-and-presentations . An investor presentation is available now, and after the webcast a replay of the webcast will also be available, at the same location on our website.

About United Therapeutics

Founded by CEO Martine Rothblatt to discover a cure for her daughter's life-threatening rare disease, pulmonary arterial hypertension, United Therapeutics transforms the treatment of rare diseases and pioneers alternatives to expand the supply of transplantable organs. From our innovative therapies to our groundbreaking manufactured organs, we are bold and unconventional. We move quickly from scientific theory to practical technologies that can save lives. As a public benefit corporation, even our legal structure reflects our commitments. We serve patients, act with integrity, create long-term shareholder value, and operate with sustainable practices that protect the future we are working to build.

Forward-Looking Statements

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements related to: our future growth and growth outlook; our portfolio of therapies and their potential to exponentially increase the number of patients that we can serve; new opportunities across cardiopulmonary and respiratory medicine; the timing of the final settlement of the September 2026 ASR; the timing, structure and use of our share repurchase program; and our goals of innovating for the unmet medical needs of our patients and to benefit our other stakeholders, furthering our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of November 4, 2026, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events, or any other reason.

ORENITRAM, REMODULIN, REMUNITY, REMUNITYPRO, TYVASO, TYVASO DPI, and UNITUXIN are registered trademarks of United Therapeutics Corporation.

ADCIRCA is a registered trademark of Eli Lilly and Company.

UNITED THERAPEUTICS CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(In millions, except per share data)
Three Months EndedSeptember 30,
2026 2025
(Unaudited)
Total revenues $ 832.5 $ 799.5
Operating expenses:
Cost of sales 99.1 100.9
Research and development 279.2 127.5
Selling, general, and administrative 146.4 182.6
Total operating expenses 524.7 411.0
Operating income 307.8 388.5
Interest income 33.7 46.4
Interest expense (2.9 ) (3.0 )
Other income, net 34.2 6.1
Total other income, net 65.0 49.5
Income before income taxes 372.8 438.0
Income tax expense (114.2 ) (99.3 )
Net income $ 258.6 $ 338.7
Net income per common share:
Basic $ 6.06 $ 7.73
Diluted $ 5.71 $ 7.16
Weighted average number of common shares outstanding:
Basic 42.7 43.8
Diluted 45.3 47.3
SELECTED CONSOLIDATED BALANCE SHEET DATA
(Unaudited, in millions)
September 30, 2026
Cash, cash equivalents, and marketable investments $ 3,535.7
Total assets 7,034.1
Total liabilities 758.1
Total stockholders’ equity 6,276.0

View source version on businesswire.com: https://www.businesswire.com/news/home/20261104979180/en/

Download PDF Version

The transaction eliminates the double-digit royalty payable to Pfizer on net sales of ralinepag

Royalty elimination applies to all formulations of ralinepag, including both oral and inhaled

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that it has entered into an amendment with Arena Pharmaceuticals, Inc. (Arena), a subsidiary of Pfizer Inc., which eliminates all royalty obligations under its exclusive license agreement related to ralinepag in exchange for an up-front payment of $525 million.

“This transaction demonstrates our confidence in the revenue opportunity for oral ralinepag, which has a pending new drug application under review by the FDA for pulmonary arterial hypertension, as well as the new dry powder inhalation formulation we are developing for a variety of pulmonary indications,” said James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics. “Ralinepag has the potential to bring substantial benefits to large patient populations spanning a number of difficult-to-treat conditions, and we expect it will transform our company in the process.”

United Therapeutics has a new drug application (NDA) under review by the U.S. Food and Drug Administration (FDA) as a once-daily, oral form of ralinepag for the treatment of pulmonary arterial hypertension (PAH), with a user fee action date of June 24, 2027. The company is also developing an inhaled version of ralinepag utilizing the dry powder inhalation (DPI) technology licensed from MannKind Corp., and plans to study ralinepag DPI for one or more of the following indications: pulmonary hypertension associated with interstitial lung disease (PH-ILD), idiopathic pulmonary fibrosis (IPF), and progressive pulmonary fibrosis (PPF).

United Therapeutics acquired the rights to ralinepag in 2018 under an exclusive license agreement with Arena which was later acquired by Pfizer Inc. The agreement provided for a low double-digit royalty on United Therapeutics’ net sales of all formulations of ralinepag. Under the license agreement, United Therapeutics will remain obligated to make the following milestone payments to Arena: (1) a one-time payment of $250.0 million for the first, if any, marketing approval in the United States for an inhaled version of ralinepag to treat PAH; (2) a one-time payment of $150.0 million for the first, if any, marketing approval in any of Japan, France, Italy, the United Kingdom, Spain, or Germany for an oral version of ralinepag to treat any indication.

Ralinepag is an investigational-stage product not approved in any jurisdiction for any indication.

About United Therapeutics

Founded by CEO Martine Rothblatt to discover a cure for her daughter's life-threatening rare disease, pulmonary arterial hypertension, United Therapeutics transforms the treatment of rare diseases and pioneers alternatives to expand the supply of transplantable organs. From our innovative therapies to our groundbreaking manufactured organs, we are bold and unconventional. We move quickly from scientific theory to practical technologies that can save lives. As a public benefit corporation, even our legal structure reflects our commitments. We serve patients, act with integrity, create long-term shareholder value, and operate with sustainable practices that protect the future we are working to build. Visit us at www.unither.com and follow us on LinkedIn , Facebook , and Instagram .

Forward-Looking Statements

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding: our efforts to develop oral ralinepag and ralinepag DPI, including our pending NDA for oral ralinepag with the FDA for PAH and our plans to develop ralinepag DPI for PH-ILD, IPF, and/or PPF; the revenue opportunity for oral ralinepag and ralinepag DPI; the potential for ralinepag has the potential to bring substantial benefits to large patient populations spanning a number of difficult-to-treat conditions, and its potential to transform our company in the process; and our goals of expanding the supply of transplantable organs, developing practical technologies that can save lives, creating long-term shareholder value, and operating with sustainable practices. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of November 4, 2026, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261104123235/en/

Download PDF Version

If successful, Treprostinil-Iloprost SMI would be the first use-as-needed combination inhaled therapy to be developed for pulmonary arterial hypertension (PAH)

_This investigational therapy combines t_wo potent prostacyclin analogues, treprostinil and iloprost, and is delivered as an inhalation spray via a soft mist inhaler for pro re nata (PRN) use

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance under the company’s Investigational New Drug application to proceed with a clinical trial of Treprostinil-Iloprost SMI.

The phase 1, open-label, single ascending dose study will evaluate the safety, tolerability, and pharmacokinetics of Treprostinil-Iloprost SMI in healthy volunteers. Assuming a successful outcome in the study, United Therapeutics anticipates commencing a subsequent phase 2 study in patients with PAH in 2027.

Treprostinil-Iloprost SMI combines two potent prostacyclin analogues, treprostinil and iloprost. The therapy is intended to be used as needed to provide episodic symptom relief for PAH patients, who may need a bridge between doses of their ongoing prostacyclin therapy due to acute symptom flare-ups.

"Many people living with PAH experience moments when their symptoms flare despite their maintenance medication, and today they have no therapy designed specifically for those moments. Treprostinil-Iloprost SMI is intended to explore whether an as-needed, combination prostacyclin therapy could help fill that gap. FDA clearance to begin clinical testing is an important first step, and we look forward to advancing this program,” said Ravi Patel, PharmD, Senior Vice President, Global Patient Safety and Strategic Clinical Development, United Therapeutics.

“As a company known for pioneering prostacyclin therapies, Treprostinil-Iloprost SMI represents another important advancement in United Therapeutics’ PAH treatment portfolio. It also reflects continued innovation from our product development platform and our culture of running down the corridors of indifference in pulmonary medicine,” said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics.

Treprostinil-Iloprost SMI is an investigational-stage product, and is not yet approved in any jurisdiction for any indication.

About Pulmonary Arterial Hypertension

PAH is a life-threatening disease that affects the blood vessels in the lungs and is characterized by increased pressure in the pulmonary arteries, due to increased pulmonary vascular resistance in the small precapillary vessels (i.e., the small blood vessels leading from the heart to lungs). The elevated pressure in the pulmonary arteries strains the right side of the heart as it pumps blood to the lungs. This eventually leads to right heart failure and, ultimately, death. PAH is characterized by structural changes in blood vessel walls, aggregation of platelets, and alteration of smooth muscle cell proliferation. PAH affects about 500,000 individuals worldwide, with around 50,000 people affected in the United States. Increases in the number of people diagnosed with the disease have been observed, but due to the rarity of the disease and the complexity of diagnosing it, only a fraction of patients with PAH are treated.

About United Therapeutics

Founded by CEO Martine Rothblatt to discover a cure for her daughter's life-threatening rare disease, pulmonary arterial hypertension, United Therapeutics transforms the treatment of rare diseases and pioneers alternatives to expand the supply of transplantable organs. From our innovative therapies to our groundbreaking manufactured organs, we are bold and unconventional. We move quickly from scientific theory to practical technologies that can save lives. As a public benefit corporation, even our legal structure reflects our commitments. We serve patients, act with integrity, create long-term shareholder value, and operate with sustainable practices that protect the future we are working to build. Visit us at www.unither.com and follow us on LinkedIn , Facebook , and Instagram .

Forward-Looking Statements

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding: the timing and design of our planned studies of Treprostinil-Iloprost SMI, including our upcoming phase 1 study in healthy volunteers and our plan to commence a phase 2 study in PAH patients in 2027; the potential benefits of Treprostinil-Iloprost SMI for PAH patients; and our goals of expanding the supply of transplantable organs, developing practical technologies that can save lives, creating long-term shareholder value, and operating with sustainable practices. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of October 28, 2026, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261028830210/en/

Prompts

United Therapeutics Corporation (ticker UTHR), listed in United States.

Company History

Date Change Detail
Aug 14, 2018 Acquired Acquired Steadymed Ltd. (CIK 1619087). Its filings from before the deal are on its own company page, not shown here.

ETFs Holding United Therapeutics Corporation

ETF Weight in ETF Shares Market value As of
PINK 9.81% 56,237 $ 32.848M Nov 17, 2026
GLRY 3.73% 12,070 $ 6.16M Aug 31, 2026
HELX 3.51% 1,809 $ 980.17K Jun 30, 2026
LFSC 3.27% 8,102 $ 4.135M Aug 31, 2026
MEDI 3.00% 2,231 $ 1.324M Nov 12, 2026
SAWG 2.66% 148 $ 76.621K Jul 31, 2026
KONG 2.55% 1,024 $ 554.834K Jun 30, 2026
GOP 2.46% 3,657 $ 2.15M Nov 17, 2026
SMRI 2.37% 28,232 $ 16.49M Nov 18, 2026
QVAL 2.27% 28,277 $ 16.52M Nov 18, 2026
FGSI 2.19% 75 $ 44.675K Nov 11, 2026
ASCE 1.26% 2,746 $ 1.488M Jun 30, 2026
TAX 1.02% 510 $ 260.294K Aug 31, 2026
BSMC 0.82% 2,525 $ 1.368M Jun 30, 2026
JMEE 0.77% 37,909 $ 22.143M Nov 17, 2026
SMDX 0.72% 1,546 $ 908.862K Nov 17, 2026
AFMC 0.68% 3,045 $ 1.79M Nov 16, 2026
AVMV 0.67% 9,450 $ 5.555M Nov 16, 2026
SIXL 0.50% 1,748 $ 1.037M Nov 12, 2026
FFF 0.41% 48 $ 26.011K Sep 30, 2026
VFMV 0.39% 3,418 $ 1.744M Aug 31, 2026
FLDZ 0.36% 27 $ 14.629K Jun 30, 2026
BDVL 0.34% 10,414 $ 6.122M Nov 16, 2026
AVMC 0.29% 2,702 $ 1.588M Nov 16, 2026
WTV 0.28% 14,957 $ 8.104M Jun 30, 2026
FTLS 0.26% 11,329 $ 0.00 Nov 16, 2026
VFMF 0.23% 4,311 $ 2.2M Aug 31, 2026
AVIE 0.21% 60 $ 35.273K Nov 16, 2026
TACU 0.19% 60 $ 35.273K Nov 17, 2026
DFLV 0.18% 23,638 $ 14.025M Nov 12, 2026
WCEO 0.17% 33 $ 17.084K Jul 31, 2026
BALI 0.17% 4,514 $ 2.654M Nov 16, 2026
JSTC 0.17% 861 $ 506.165K Nov 17, 2026
REMC 0.16% 10 $ 5,418.30 Jun 30, 2026
TMSL 0.15% 7,695 $ 4.169M Jun 30, 2026
VFQY 0.15% 1,507 $ 769.143K Aug 31, 2026
DVAL 0.15% 199 $ 107.824K Jun 30, 2026
DFVX 0.14% 1,355 $ 803.935K Nov 12, 2026
MODL 0.13% 2,523 $ 1.367M Jun 30, 2026
AVSU 0.13% 1,075 $ 631.971K Nov 16, 2026
ESUM 0.13% 455 $ 235.558K Jul 31, 2026
DXUV 0.13% 13,543 $ 8.035M Nov 12, 2026
VFMO 0.13% 4,802 $ 2.451M Aug 31, 2026
DFUV 0.12% 32,566 $ 19.322M Nov 12, 2026
AVUQ 0.12% 847 $ 497.934K Nov 16, 2026
FLSP 0.12% 2,055 $ 1.113M Jun 30, 2026
ENHU 0.11% 17 $ 9,993.96 Nov 16, 2026
DYNF 0.11% 79,908 $ 46.976M Nov 16, 2026
THEQ 0.09% 53 $ 31.158K Nov 17, 2026
AVUS 0.08% 20,789 $ 12.221M Nov 16, 2026
AVLC 0.08% 2,197 $ 1.292M Nov 16, 2026
DCOR 0.08% 60,719 $ 36.025M Nov 12, 2026
DFAC 0.08% 117,342 $ 69.62M Nov 12, 2026
MSSM 0.08% 1,095 $ 558.866K Aug 31, 2026
VSLU 0.05% 546 $ 295.839K Jun 30, 2026
IALT 0.05% 6,785 $ 3.989M Nov 16, 2026
DFAU 0.04% 9,508 $ 5.641M Nov 12, 2026
DFUS 0.03% 11,898 $ 7.059M Nov 12, 2026
MSLC 0.02% 1,643 $ 838.554K Aug 31, 2026
FEAC 0.02% 9 $ 4,876.47 Jun 30, 2026
NTSD 0.02% 10 $ 5,418.30 Jun 30, 2026
GDE 0.01% 101 $ 51.548K Aug 31, 2026
EBI 0.01% 145 $ 74.005K Aug 31, 2026
NTSX 0.01% 239 $ 129.497K Jun 30, 2026
NTRL 0.00% 358 $ 0.00 Nov 16, 2026